Compare MRCC & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCC | IPSC |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 189.7M |
| IPO Year | 2011 | 2021 |
| Metric | MRCC | IPSC |
|---|---|---|
| Price | $4.82 | $2.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 142.0K | ★ 972.0K |
| Earning Date | 06-08-2026 | 06-16-2026 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $4.11 | $0.34 |
| 52 Week High | $7.92 | $2.97 |
| Indicator | MRCC | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 38.97 | 52.38 |
| Support Level | $4.11 | $0.49 |
| Resistance Level | $6.91 | $2.71 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 33.73 | 30.06 |
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.